EMERYVILLE, Calif. , Feb. 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the pricing of its upsized initial public
The proprietary process, called Ingenui-T, utilizes whole blood from a standard blood draw The novel process is designed to elevate the CAR T cell patient experience by offering a less-invasive alternative to apheresis as well as substantial reduction of cost through a minimization of the CAR
The announcement follows the recent IND clearance for KYV-101 to be used in Kyverna’s KYSA-7 Phase 2 open-label, multicenter study KYV-101 is a fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases EMERYVILLE, Calif., January 19, 2024 – Kyverna
The seventh IND clearance will expand use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-7 clinical trial targeting a large patient demographic KYV-101 is a fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases EMERYVILLE, Calif.,